

## UNITED STATE DEPARTMENT OF COMMERCE Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.
07/313,91	.1 02/23/8	9 SHEPHERD	A	UTSK097BAH
				EXAMINER
F.O. EOX		GEIE:	43693	IEIERGIPAPER NUMBER
HOUSTON,	TX 77210	•	Ant Oldi	<u> </u>
			2	<b>6</b> 185
			DATE MAILED:	
This is a communication from COMMISSIONER OF PATEN	the examiner in charge of TS AND TRADEMARKS	f your application.		04/03/90
			,	
This application has been	n examined Re	sponsive to communication filed on	[	This action is made final.
A shortened statutory period	for response to this as	ction is set to expire3_ month(s),	days fro	m the date of this letter.
		ill cause the application to become abandone	id. 35 U.S.C. 133	
Pert I THE FOLLOWING A	TTACHMENT(S) AR	E PART OF THIS ACTION:		
1. Notice of Referen			re Patent Drawing,	
	d by Applicant, PTO-1 w to Effect Drawing C		of Informal Patent	Application, Form PTO-152
S. [_] Information on Ac	W ID Ellow Diawing C	manges, P10-1474.		· · · · · · · · · · · · · · · · · · ·
Part II SUMMARY OF AC	TION			
1. Claims / -	19			are pending in the application.
Of the abo	ve, claims			are withdrawn from consideration.
2. Claims				have been cancelled.
3. Claims				are allowed.
4. X Claims 1- 14				
<u> </u>				
6. Claims			are subject to restric	ction or election requirement.
7. This application h	as been filed with info	ormal drawings under 37 C.F.R. 1.85 which a	re acceptable for ex	amination purposes.
8. Formal drawings	are required in respor	se to this Office action.		
		ave been received on e (see explanation or Notice re Patent Drawin		ter 37 C.F.R. 1.84 these drawings
		sheet(s) of drawings, filed on niner (see explanation).	has (have) been	n 🔲 approved by the
11. The proposed dra	wing correction, filed	has been 🔲 appr	oved; 🔲 disapprov	ed (see explanation).
12. Acknowledgement is made of the claim for priority under U.S.C. 119. The certified copy has been received been filed in parent application, serial no; filed on				
	***	condition for allowance except for formal ma parte Quayle, 1935 C.D. 11; 453 O.G. 213.	tters, prosecution as	to the merits is closed in
14. Other				•

**EXAMINER'S ACTION** 

Art Unit 255

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless-

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for patent.
- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one (1) year prior to the date of application for patent in the United States.

The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) and (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

Claim 14 is rejected under 35 U.S.C. 102(a) and (b) as being anticipated by Anderson et al.

See figure 1, page 176. There is provided a controllable source of monochromatic light (section 3.3, page 178) and a cuvette for holding a sample of whole, undiluted blood; see page 174 for a discussion of the use of such tests with whole undiluted/blood. The

device of Anderson et al was used with an optical absorbance path through the sample of .011 cm, or 110 micrometers, which is in the instant disclosed range of 80 to 150 micrometers disclosed as being the range which minimizes the effect of light scattering. There is a light detector which is positioned to receive and detect light from the source of light passing through the sample; the detector is positioned and has a light detecting area which minimizes the effect of length scattering by the sample. The "light detector" either can be viewed as including the integrating sphere or as not, in either case the claim does not exclude an optical means, such as the integrating sphere, being a part of the apparatus.

Claims 1,2 and 6 through 14 are rejected under 35 U.S.C. 103 as being unpatentable over Anderson et al.

See the discussion of the Anderson et al reference above. The wavelengths used by Anderson et al, in the range from 500 to 620 nanometers, and in particular 505,520, 530 and 560 nanometers (page 179) is virtually identical with the range disclosed on page 7 of the instant specification, which runs from 506 to 620 nanometers, which are disclosed as being those which minimize the effect of radiation scattering and maximize radiation absorbance of blood. Of the particular wavelengths disclosed on page 179 of the reference two (520 and 560 nanometers) are the same as specific wavelengths mentioned on page 7 of the instant specification, and a

Serial No. 313,911
Art Unit 255

third (505 nanometers) differs from another instant disclosed wavelength (506 nanometers) by only one nanometer.

The use of such optical density measurements are known to be usable to calculate blood components; the Anderson et al reference makes reference to the use of such to calculate oxygen saturation (page 182, section 4.2. first sentence, for example). It would have been obvious to use measurements from such an instrument to calculate blood constituents because such use of optical absorbances for such calculations is known and such a use is at least suggested by the Anderson reference in its mention of the use of the data in oxygen situration measurement.

While Anderson et al used a spectrophotometer to generate the particular wavelengths of interest other known methods of generating the desired wavelengths, such as a tunable laser, interference filters or the like would have been obvious because it is the provision of the particular wavelengths of interest, and not the means for providing them, which provides the data of interest.

Claims 3 through 5 are rejected under 35 U.S.C. 103 as being unpatentable over Anderson et al. as applied to claim 1 above, and further in view of Shibata.

Anderson et al discusses the problem of light scatter, and uses a detector arrangement, with an integrating sphere, to capture substantially all of the

Art Unit 255

light which passes through the sample in a generally forward direction. It is known that this same capturing of substantially all forwardly directed light can be achieved by using a large detector placed close to the sample; see figures 2A,2B and 4 of Shibata et al. and column 3, lines 17 through 27. The use of such a large close detector would have been obvious because it is a known alternative method for obtaining the same desired result and does not require the additional presence of an integrating sphere.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to R.A. Rosenberger whose telephone number is (703) 557-4347.

Any inquiry of a general nature, or relating to the status of this application, should be directed to the Group receptionist whose telephone number is (703) 557-3311.

Rosenberger/rk 3/10/90

RICHARD A. ROSENBERGER EXAMINER

ART UNIT 255